Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,102
  • Shares Outstanding, K 13,572
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,900 K
  • 60-Month Beta 1.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 22.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.45
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.60
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.85 +7.91%
on 08/11/20
19.47 -50.95%
on 07/27/20
-1.52 (-13.73%)
since 07/10/20
3-Month
5.22 +82.85%
on 05/15/20
19.47 -50.95%
on 07/27/20
+3.91 (+69.42%)
since 05/12/20
52-Week
4.71 +102.76%
on 04/22/20
19.47 -50.95%
on 07/27/20
+2.65 (+38.41%)
since 08/12/19

Most Recent Stories

More News
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Is (ATNM) Outperforming Other Medical Stocks This Year?

ATNM : 9.55 (-1.14%)
Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split

, /PRNewswire/ --   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Board of Directors approved a 1-for-30 reverse split of its issued and outstanding common stock that...

ATNM : 9.55 (-1.14%)
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?

Does Actinium Pharmaceuticals (ATNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

ATNM : 9.55 (-1.14%)
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues In Line

Pacira (PCRX) misses on earnings for the second quarter of 2020 while its revenues meet the mark.

BLRX : 2.02 (+1.00%)
PCRX : 61.22 (+2.10%)
BLCM : 7.04 (-0.42%)
ATNM : 9.55 (-1.14%)
Thinking about buying stock in Carnival Corp, Actinium Pharmaceuticals, United Airlines Holdings, Uber Technologies, or Fastly Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCL, ATNM, UAL, UBER, and FSLY.

ATNM : 9.55 (-1.14%)
CCL : 15.19 (-3.98%)
UBER : 30.84 (-1.19%)
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -1.67% move from the previous day.

ATNM : 9.55 (-1.14%)
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

TBIO : 14.48 (+1.76%)
PCRX : 61.22 (+2.10%)
ACRX : 1.2200 (unch)
ATNM : 9.55 (-1.14%)
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $0.59, marking a -0.78% move from the previous day.

ATNM : 9.55 (-1.14%)
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

Is (ATNM) Outperforming Other Medical Stocks This Year?

ATNM : 9.55 (-1.14%)
Thinking about buying stock in Vivint Solar, Actinium Pharmaceuticals, Delta Air Lines, Sunesis Pharmaceuticals, or Novan Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSLR, ATNM, DAL, SNSS, and NOVN.

ATNM : 9.55 (-1.14%)
DAL : 29.09 (-1.86%)
NOVN : 0.5799 (-6.47%)
VSLR : 24.77 (+6.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATNM with:

Business Summary

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition...

See More

Key Turning Points

2nd Resistance Point 10.51
1st Resistance Point 10.03
Last Price 9.55
1st Support Level 9.07
2nd Support Level 8.59

See More

52-Week High 19.47
Fibonacci 61.8% 13.83
Fibonacci 50% 12.09
Fibonacci 38.2% 10.35
Last Price 9.55
52-Week Low 4.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar